FOXP3 Allelic Variants and Haplotype Structures Are Associated with Aggressive Breast Cancer Subtypes

Table 1

Prognostic parameters in total BC sample and in aggressive subtypes.

Prognostic parameters		Total BC	LB	HER2+	TN
Tumor size	<1.5 cm	10 (8.9%)	3 (8.3%)	2 (8.7%)	5 (9.4%)
	1.5–3.0 cm	57 (50.9%)	23 (63.9%)	14 (60.9%)	20 (37.8%)
	>3.0 cm	45 (40.2%)	10 (27.8%)	7 (30.4%)	28 (52.8%)
TNM staging	I	19 (18.1%)	7 (20%)	5 (19.2%)	7 (15.9%)
	II	39 (37.2%)	14 (40%)	8 (30.8%)	17 (38.6%)
	III	37 (35.2%)	12 (34.3%)	9 (34.6%)	16 (36.4%)
	IV	10 (9.5%)	2 (5.7%)	4 (15.4%)	4 (9.1%)
Histological grade	II	30 (26.8%)	12 (33.3%)	8 (34.8%)	10 (18.9%)
	III	82 (73.2%)	24 (66.7%)	15 (65.2%)	43 (81.1%)
Ki-67	Low	7 (8.8%)	4 (19.0%)	0 (0.0%)	3 (7.3%)
	Moderate	25 (31.2%)	9 (42.9%)	7 (46.7%)	9 (23.6%)
	High	48 (60.0%)	8 (38.1%)	8 (53.3%)	32 (69.1%)
Lymph nodes commitment	No	54 (49.1%)	19 (52.8%)	12 (52.2%)	23 (45.1%)
	Yes	56 (50.9%)	17 (47.2%)	11 (47.8%)	28 (54.9%)

LB: Luminal B HER+; HER2+: HER2-enriched; TN: triple-negative.